Literature DB >> 16478402

Individual HIV type 1 envelope-specific T cell responses and epitopes do not segregate by virus subtype.

S A Brown1, K S Slobod, S Surman, A Zirkel, X Zhan, J L Hurwitz.   

Abstract

HIV-1 vaccines are often designed to target one or several virus subtype(s). They therefore include antigens (e.g., env or env/gag/pol) from each targeted subtype to elicit subtype-directed immunity. To determine if individual T cells respond to HIV-1 antigens in a subtype-directed manner, we selected four T cell hybridomas, each representative of a different immunodominant response toward a subtype B envelope. Hybridomas were tested for responses toward 20 subtype B envelope proteins and one protein each from subtypes A, C, and D. None of the hybridomas cross-reacted with all subtype B envelopes, yet three responded to a non-B protein. Core epitopes and flanking regions affected responsiveness. This lack of subtype-directed activity was corroborated by analyses of the Los Alamos database; like immune responses, epitope distributions were not dictated by subtype. Results highlight the difficulty of predicting immune responses based on subtype alone and encourage considerations of antigenic disparity in addition to subtype disparity during HIV-1 vaccine design.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16478402     DOI: 10.1089/aid.2006.22.188

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

Review 1.  The challenge of HIV-1 subtype diversity.

Authors:  Barbara S Taylor; Magdalena E Sobieszczyk; Francine E McCutchan; Scott M Hammer
Journal:  N Engl J Med       Date:  2008-04-10       Impact factor: 91.245

2.  UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.

Authors:  Bart G Jones; Robert E Sealy; Xiaoyan Zhan; Pamela J Freiden; Sherri L Surman; James L Blanchard; Julia L Hurwitz
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

3.  A Multi-Vector, Multi-Envelope HIV-1 Vaccine.

Authors:  Julia L Hurwitz; Xiaoyan Zhan; Scott A Brown; Mattia Bonsignori; John Stambas; Timothy D Lockey; Bart Jones; Sherri Surman; Robert Sealy; Pam Freiden; Kristen Branum; Karen S Slobod
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

4.  Target peptide sequence within infectious human immunodeficiency virus type 1 does not ensure envelope-specific T-helper cell reactivation: influences of cysteine protease and gamma interferon-induced thiol reductase activities.

Authors:  Robert Sealy; Wendy Chaka; Sherri Surman; Scott A Brown; Peter Cresswell; Julia L Hurwitz
Journal:  Clin Vaccine Immunol       Date:  2008-01-30

Review 5.  Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.

Authors:  Robert Sealy; Karen S Slobod; Patricia Flynn; Kristen Branum; Sherri Surman; Bart Jones; Pamela Freiden; Timothy Lockey; Nanna Howlett; Julia L Hurwitz
Journal:  Int Rev Immunol       Date:  2009       Impact factor: 5.311

6.  How Basic Immunological Principles May Instruct the Design of a Successful HIV-Type 1 Vaccine.

Authors:  Karen S Slobod; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-04       Impact factor: 2.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.